Business Areas
30 Respiratory
Nitric oxide has long been recognized as a potent antimicrobial molecule produced by the human immune system. However, therapeutic use of nitric oxide has historically been limited to inhalation of nitric oxide as a gas, which has inherent weaknesses:
- toxicity at high doses
- difficulty controlling dosing
- airway irritation.
The innovation of the RESP platform lies not in nitric oxide itself but in the formulation engineering that enables controlled nitric oxide generation within the narrow physiological window required for safe pulmonary therapy.
30 Respiratory has developed RESP303 as a first-in-class inhaled antimicrobial therapy that generates nitric oxide directly at the airway surface to treat chronic multidrug-resistant respiratory infections. This engineering enables nitric oxide to be generated directly at the airway surface where pathogens reside, while minimizing systemic exposure and maintaining airway tolerability.
RESP301 was the first clinical formulation used to establish dosing and safety parameters and RESP303 represents the second-generation optimized formulation of the RESP platform. To date 206 patients have received RESP formulations across clinical studies.
In the recent NOPA Phase 1b/2a study evaluating RESP303 in bronchiectasis patients with chronic multidrug-resistant Pseudomonas aeruginosa infection. Key findings included; sustained reductions in sputum bacterial load during treatment; persistence of antimicrobial effect after treatment ended; improvements in patient global impression scores, and favourable safety and tolerability profile.
The observation of post-treatment durability of bacterial suppression is particularly important because inhaled antibiotics typically show rapid bacterial rebound once treatment cycles end.
RESP303 represents a fundamentally different approach to antimicrobial therapy. Unlike conventional antibiotics that target specific microbial pathways, nitric oxide exerts antimicrobial activity through multiple simultaneous biochemical mechanisms. This multi-target mechanism reduces the likelihood of resistance development and enables activity against pathogens embedded in biofilms.
RESP303 could establish a new class of inhaled antimicrobial therapies designed specifically for multidrug-resistant airway infections.
- Chronic airway infections in diseases such as bronchiectasis and cystic fibrosis represent a significant and growing healthcare burden.
- Patients with chronic Pseudomonas aeruginosa infection experience increased exacerbations, hospitalizations, and progressive lung damage.
- Existing therapies often suppress infection temporarily but rarely achieve durable pathogen control.
A therapy capable of sustained antimicrobial suppression could therefore represent a significant clinical and commercial opportunity.
Beyond the initial bronchiectasis indication, the RESP platform support additional respiratory applications including:
- non-tuberculous mycobacterial infection
- cystic fibrosis infections
- viral respiratory infections
Tuberculosis
Tuberculosis (TB) infects 10.6 million people annually and is responsible for over 1.6 million deaths. This devastating burden of disease is growing year on year and disproportionately affects patients in developing countries. In response, we have commenced a program to develop anti-TB therapies and have completed a comprehensive preclinical program. Our lead candidate is planned to enter Phase II early bactericidal activity studies in newly diagnosed TB patients in October this year.
30 Therapeutics
Oral health
An ageing population and increased awareness of the profound impacts of poor oral health have driven an explosion in the number and complexity of oral surgeries undertaken every year. Many of these are complicated by infection which leads to serious long-term consequences. Unfortunately, the mouth represents a unique challenge for conventional antibiotics being both polymicrobial and difficult to penetrate. 30 Technology is ideally positioned to develop a range of solutions that can prevent or treat these surgical and implant related infections
Ophthalmology
Nitric oxide is intimately involved in regulation of infection and ocular pressure. We are actively exploring utilising its technology in topical formulations that can be used in a wide variety of infectious and pathological conditions.
Rare diseases
An absolute or functional deficiency of nitric oxide plays a critical role in several diseases that, whilst severe, affect smaller populations. Our platform technology shows promise both as a means of returning tissue NO back to physiological levels and to deliver broad spectrum antimicrobial activity.